Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway

Blood (2024) 144 (Supplement 1): 73.

https://doi.org/10.1182/blood-2024-205557

Published: 2024

Journal Articles

Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies

Binu Kandathilparambil Sasi, Chiara Tarantelli, Elisa Civanelli, Eleonora Cannas, Stacey M Fernandes, Samantha J. Shupe, Michael Lahn, Lars van der Veen, Giusy Di Conza, Francesco Bertoni, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2023-180073

Published: 2023

Journal Articles

PI3K and BTK Inhibition Induces the Upregulation of CD19 and Increases Sensitivity to CAR T Cells in a Model of Marginal Zone Lymphoma (MZL)

Sisi Wang, Alberto J Arribas, Chiara Tarantelli, Amandine Pradier, Lodovico Terzi Di Bergamo, Emanuele Zucca, Davide Rossi, Federico Simonetta, Francesco Bertoni

Blood (2022) 140 (Supplement 1): 4554–4555.

https://doi.org/10.1182/blood-2022-168625

Published: 2022

Journal Articles

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Filippo Spriano, Gaetanina Golino, PhD, Lorenzo Scalise, Emanuele Zucca, MD, Anastasios Stathis, MD, Patrick H Van Berkel, PhD, Francesca Zammarchi, PhD, Francesco Bertoni, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-134664

Published: 2020

Journal Articles

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Patrizia Mondello, MD PhD MSc, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Alberto Arribas, PhD, Andrea Rinaldi, Anas Younes, MD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2858.

https://doi.org/10.1182/blood-2019-125123

Published: 2019

Journal Articles

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Alberto J Arribas, Sara Napoli, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Alessandra Di Veroli, Chiara Tarantelli, PhD, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, PhD, Andrea Rinaldi, Anastasios Stathis, MD, Georg Stuessi, MD, Valter Gattei, MD, Gabriele Cruciani, Emanuele Zucca, MD, Davide Rossi, MD PhD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2569.

https://doi.org/10.1182/blood-2019-124299

Published: 2019

Journal Articles

New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease

Blood (2018) 132 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2018-99-112763

Published: 2018

Journal Articles

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

Filippo Spriano, Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Gaetanina Golino, Luciano Cascione, PhD, Emanuele Zucca, Anastasios Stathis, MD, Francis J. Giles, MD FRCPI, FRCPath, Francesco Bertoni, MD

Blood (2018) 132 (Supplement 1): 4174.

https://doi.org/10.1182/blood-2018-99-114900

Published: 2018

Journal Articles

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Elaine Y Chung, PhD, Filippo Spriano, Ivo Kwee, PhD, Sara Napoli, Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Andrea Cavalli, Alberto Arribas, PhD, Andrea Rinaldi, Davide Rossi, MD PhD, Emanuele Zucca, MD, Anastasios Stathis, MD, Katti Jessen, PhD, Brian J Lannutti, PhD, Jeffrey Toretsky, MD, Francesco Bertoni, MD

Blood (2017) 130 (Supplement 1): 2810.

https://doi.org/10.1182/blood.V130.Suppl_1.2810.2810

Published: 2017

Journal Articles

Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax

Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, Petra Hillmann, Filippo Spriano, Ivo Kwee, PhD, Andrea Rinaldi, PhD, Anastasios Stathis, Emanuele Zucca, Doriano Fabbro, Vladimir Cmiljanovic, Francesco Bertoni, MD

Blood (2016) 128 (22): 3017.

https://doi.org/10.1182/blood.V128.22.3017.3017

Published: 2016

Journal Articles

TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL

Katayoun Jessen, PhD, Eric Moseley, PhD, Elaine Yee Lin Chung, PhD, Lauren Otuski, BS, Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, James Breitmeyer, MD PhD, James Freddo, MD, Jeffrey Toretsky, MD, Francesco Bertoni, MD, Brian J Lannutti, PhD

Blood (2016) 128 (22): 4035.

https://doi.org/10.1182/blood.V128.22.4035.4035

Published: 2016

Journal Articles

The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents

Eugenio Gaudio, PhD, Ivo Kwee, PhD, Filippo Spriano, Chiara Tarantelli, PhD, Andrea Rinaldi, PhD, Thibaud Jourdan, Melanie Berthold, Alberto Arribas, PhD, Anastasios Stathis, Davide Rossi, MD PhD, Martin Lange, PhD, Oliver Politz, Emanuele Zucca, Francesco Bertoni, MD

Blood (2016) 128 (22): 4185.

https://doi.org/10.1182/blood.V128.22.4185.4185

Published: 2016

Journal Articles

Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529

Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Alberto Arribas, PhD, Luciano Cascione, PhD, Ivo Kwee, PhD, Andrea Rinaldi, PhD, Maurilio Ponzoni, MD, Roberta Pittau Bordone, Georg Stussi, MD, Davide Rossi, MD PhD, Emanuele Zucca, Anastasios Stathis, Callum Sloss, PhD Molecular Biology, Francesco Bertoni, MD

Blood (2016) 128 (22): 4187.

https://doi.org/10.1182/blood.V128.22.4187.4187

Published: 2016

Journal Articles

The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Eugenio Gaudio, Luciano Cascione, Maurilio Ponzoni, MD, Chiara Tarantelli, Elena Bernasconi, Maria Eugenia Riveiro, PhD, Esteban Cvitkovic, MD, Emanuele Zucca, Francesco Bertoni

Blood (2015) 126 (23): 5119.

https://doi.org/10.1182/blood.V126.23.5119.5119

Published: 2015

Journal Articles

The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas

Chiara Tarantelli, Eugenio Gaudio, Ivo Kwee, Luciano Cascione, Elena Bernasconi, Petra Hillmann, Anastasios Stathis, MD, Georg Stussi, MD, Doriano Fabbro, Andreas Wicki, Emanuele Zucca, Vladimir Cmiljanovic, Francesco Bertoni

Blood (2015) 126 (23): 4005.

https://doi.org/10.1182/blood.V126.23.4005.4005

Published: 2015

Journal Articles

The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma

Elena Bernasconi, B.Sc., Chiara Tarantelli, Eugenio Gaudio, PhD, Ivo Kwee, Andrea Rinaldi, Luciano Cascione, Anastasios Stathis, MD, Maria Eugenia Riveiro, MD PhD, Emanuele Zucca, MD, Francesco Bertoni

Blood (2014) 124 (21): 3113.

https://doi.org/10.1182/blood.V124.21.3113.3113

Published: 2014

Journal Articles

BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma

Luciano Cascione, Eugenio Gaudio, PhD, Elena Bernasconi, B.Sc., Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, B.Sc., Riccardo Bomben, Valter Gattei, Ivo Kwee, PhD, Anastasios Stathis, MD, Maria Eugenia Riveiro, MD PhD, Emanuele Zucca, MD, Francesco Bertoni

Blood (2014) 124 (21): 4495.

https://doi.org/10.1182/blood.V124.21.4495.4495

Published: 2014

Journal Articles

The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response

Chiara Tarantelli, Eugenio Gaudio, PhD, Ivo Kwee, PhD, Andrea Rinaldi, Matteo Stifanelli, Elena Bernasconi, B.Sc., Chiara Barassi, Petra Hillmann, Anastasios Stathis, MD, Laura Carrassa, Massimo Broggini, Georg Stussi, MD, Doriano Fabbro, Paul Hebeisen, Frances Betts, Andreas Wicki, Emanuele Zucca, MD, Vladimir Cmiljanovic, Francesco Bertoni

Blood (2014) 124 (21): 1782.

https://doi.org/10.1182/blood.V124.21.1782.1782

Published: 2014

NARROW

Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK Pathway

Novel Pi3kδ Inhibitor Roginolisib Synergizes with the Bcl-2 Inhibitor Venetoclax in Hematological Malignancies

PI3K and BTK Inhibition Induces the Upregulation of CD19 and Increases Sensitivity to CAR T Cells in a Model of Marginal Zone Lymphoma (MZL)

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

New Molecular and Therapeutic Insights into Canine Diffuse Large B Cell Lymphoma Elucidates the Role of the Dog As a Model for Human Disease

Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax

TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL

The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents

Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMGN529

The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas

The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma

BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma

The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only